Related Experiment Video
Updated: May 22, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
[Atrial fibrillation in 2025: Diagnosis and treatment]
Jean-Marc Sellal1, Néfissa Hammache1, Mathieu Echivard1
1Département de cardiologie, CHRU de Nancy, 1, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France; IADI, Inserm U1254, Université de Lorraine, Nancy, 1, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.
Insights
Atrial fibrillation (AF), the most common heart rhythm disorder, significantly raises stroke risk. Early diagnosis and risk assessment using the CHA2DS2-VA score are crucial for timely anticoagulant treatment and stroke prevention.
Area of Science:
- Cardiology
- Electrophysiology
- Preventive Medicine
Context:
- Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia.
- AF significantly increases risks of stroke, heart failure, cognitive decline, hospitalization, and mortality.
- Early diagnosis of AF is critical for preventing severe complications, particularly ischemic stroke.
Purpose:
- To highlight the importance of diagnosing atrial fibrillation (AF).
- To emphasize the role of the CHA2DS2-VA score in assessing embolic risk and guiding anticoagulant therapy.
- To discuss advancements in AF detection and management strategies.
Summary:
- Atrial fibrillation (AF) necessitates prompt diagnosis and embolic risk stratification using the CHA2DS2-VA score.
- Anticoagulant therapy is vital for patients identified as high-risk.
- Novel technologies, such as smartwatches, are improving AF detection.
- Treatment options include heart rate or rhythm control, with catheter ablation emerging as an alternative to antiarrhythmic drugs.
- Managing risk factors is key for AF prevention and long-term sinus rhythm maintenance.
Impact:
- Improved patient outcomes through timely diagnosis and appropriate treatment of AF.
- Reduced incidence of AF-related ischemic strokes and other cardiovascular complications.
- Potential for widespread AF screening and early intervention using new technologies.
Abstract:
Atrial fibrillation (AF) is the most common arrhythmia. It increases the risk of hospitalization, heart failure, cognitive decline and mortality. It is the first cause of ischemic stroke. These are largely preventable if AF is diagnosed. It is essential to estimate the patient's embolic risk using the CHA2DS2-VA score, which now replaces the CHADS-Vasc score. Patients who require it must receive adequate anticoagulant treatment. New technologies (in particular, smart-watch) have led to advances in the detection and diagnosis of this arrhythmia. Patients suffering from AF may be treated with a heart rate control strategy (to limit tachycardia) or a rhythm control strategy (to maintain sinus rhythm). Catheter ablation is increasingly being offered to patients as an alternative to antiarrhythmic therapy. Controlling risk factors is essential to prevent the onset of AF, and to try to maintain sinus rhythm over the long term.
Related Concept Videos
01:28Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...